85. 特発性間質性肺炎 Idiopathic interstitial pneumonia Clinical trials / Disease details

臨床試験数 : 598 / 薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210

346 trials found

diseases per page:

Showing 1 to 10 of 346 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05255991 (ClinicalTrials.gov)	September 2022	15/2/2022	Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmo ...	A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Saf ...	Idiopathic Pulmonary Fibrosis;Interstitial Lung Disease	Drug: Placebo;Drug: Inhaled Treprostinil;Device: Treprostinil Ultrasonic Nebulizer	United Therapeutics	NULL	Not yet recruiting	40 Years	N/A	All	396	Phase 3	NULL
2	NCT05195918 (ClinicalTrials.gov)	April 1, 2022	2/12/2021	Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients	Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients Wi ...	Idiopathic Pulmonary Fibrosis	Combination Product: EGCG + Nintedanib;Combination Product: EGCG + Pirfenidone;Combination Product: ...	Hal Chapman	University of Michigan;Cornell University;Massachusetts General Hospital;Temple University	Not yet recruiting	40 Years	85 Years	All	50	Phase 1	United States
3	EUCTR2021-001253-32-GR (EUCTR)	04/03/2022	27/12/2021	A Study to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pul ...	A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate ...	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Code: HZN-825 INN or Proposed INN: HZN-825 Other descriptive name: SAR100842	Horizon Therapeutics Ireland DAC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	360	Phase 2	United States;Taiwan;Greece;Spain;Turkey;Chile;United Kingdom;Italy;France;Mexico;Canada;Argentina;B ...
4	NCT05154240 (ClinicalTrials.gov)	February 21, 2022	17/11/2021	A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects ...	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Oral Single and Multiple Ascending Doses, P ...	Idiopathic Pulmonary Fibrosis	Drug: INS018_055;Drug: Placebo	InSilico Medicine Hong Kong Limited	NULL	Not yet recruiting	18 Years	55 Years	All	80	Phase 1	New Zealand
5	EUCTR2021-001253-32-ES (EUCTR)	16/02/2022	07/12/2021	A Study to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pul ...	A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate ...	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Code: HZN-825 INN or Proposed INN: HZN-825 Other descriptive name: SAR100842	Horizon Therapeutics Ireland DAC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	360	Phase 2	United States;Taiwan;Greece;Spain;Turkey;Chile;United Kingdom;Italy;France;Mexico;Canada;Argentina;P ...
6	NCT05130970 (ClinicalTrials.gov)	January 27, 2022	12/11/2021	CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis	A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, a ...	Idiopathic Pulmonary Fibrosis	Drug: CSL312;Drug: Placebo	CSL Behring	NULL	Recruiting	40 Years	N/A	All	80	Phase 2	United States;Canada
7	JPRN-jRCT2051210169	16/01/2022	05/02/2022	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in ...	Idiopathic Pulmonary Fibrosis	Pamrevlumabor placebo, 30 mg/kg, IV, Day 1 and every 3 weeks thereafter, up to Week 48, for a total ...	Tracy Ganske	NULL	Recruiting	>= 40age old	<= 85age old	Both	34	Phase 3	United States;Argentina;Chile;Russia;Australia;Taiwan;Hong Kong;South Korea;the People's Republic of ...
8	NCT03720483 (ClinicalTrials.gov)	January 2022	18/7/2018	Inhaled NAC in Treatment of IPF	Pilot Study to Evaluate Inhaled N-Acetylcysteine in Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis (IPF)	Drug: N-acetyl cysteine then Placebo;Drug: Placebo then N-acetyl cysteine	University of Colorado, Denver	NULL	Withdrawn	40 Years	75 Years	All	0	Phase 1/Phase 2	United States
9	JPRN-jRCT2051210129	05/12/2021	05/12/2021	A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY O ...	A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY O ...	Idiopathic pulmonary fibrosis	RO7490677 (PRM-151) is administered intravenously at 10 mg / kg every 4 weeks for 48 weeks.	Makino Ryoko	NULL	Recruiting	>= 40age old	<= 85age old	Both	60	Phase 3	Spain;Sweden;Japan;Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Fi ...
10	NCT05134727 (ClinicalTrials.gov)	November 18, 2021	15/11/2021	Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascend ...	A Double-blind, Randomized, Placebo-controlled Study in Healthy Volunteers to Investigate the Safety ...	Idiopathic Pulmonary Fibrosis	Drug: AZD5055;Drug: Placebo	AstraZeneca	NULL	Recruiting	18 Years	45 Years	All	104	Phase 1	United States

First Previous1 2 3 4 5…35Next Last